siRNA targeting ANGPTL3 stands in the spotlight for lipid-lowering therapy

• Bo Hu,
• Yuanyu Huang

Affiliations

Bo Hu

School of Life Science, Beijing Institute of Technology, Beijing 100081, China; Advanced Research Institute of Multidisciplinary Science, Beijing Institute of Technology, Beijing 100081, China; School of Medical Technology, Beijing Institute of Technology, Beijing 100081, China; Key Laboratory of Molecular Medicine and Biotherapy, Beijing Institute of Technology, Beijing 100081, China; Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering, Beijing Institute of Technology, Beijing 100081, China

Yuanyu Huang

School of Life Science, Beijing Institute of Technology, Beijing 100081, China; Advanced Research Institute of Multidisciplinary Science, Beijing Institute of Technology, Beijing 100081, China; School of Medical Technology, Beijing Institute of Technology, Beijing 100081, China; Key Laboratory of Molecular Medicine and Biotherapy, Beijing Institute of Technology, Beijing 100081, China; Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering, Beijing Institute of Technology, Beijing 100081, China; School of Materials and the Environment, Beijing Institute of Technology, Zhuhai 519085, China; Rigerna Therapeutics, Suzhou, Jiangsu 215127, China; Corresponding author: Yuanyu Huang, School of Life Science, Beijing Institute of Technology, Beijing 100081, China.